Ark Therapeutics Group Plc (AKT.L) Monday announced that it has been selected to manufacture and supply Lymfactin to Laurantis Pharma under a conditional agreement.
The leading viral product focused contract development and manufacturing services company further stated that it has signed a manufacturing agreement with Laurantis Pharma, a privately held clinical-stage biotechnology company with a broad portfolio of first-in-class products based on two proprietary technologies, for Production of Lymfactin Investigational Treatment for Breast Cancer-Associated Lymphedema.
The Group stated that the agreement is subject to Laurantis receiving regulatory approval to commence its phase I clinical trial. Further, specific terms of the agreement between the two companies have not been disclosed.
For comments and feedback contact: editorial@rttnews.com
Business News